Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1126503.RALsmwngbc0fyEwu9DAtxaOzlwVw4QTXpm5bflzIubMWU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1126503.RALsmwngbc0fyEwu9DAtxaOzlwVw4QTXpm5bflzIubMWU130_assertion type Assertion NP1126503.RALsmwngbc0fyEwu9DAtxaOzlwVw4QTXpm5bflzIubMWU130_head.
- NP1126503.RALsmwngbc0fyEwu9DAtxaOzlwVw4QTXpm5bflzIubMWU130_assertion wasGeneratedBy ECO_0000203 NP1126503.RALsmwngbc0fyEwu9DAtxaOzlwVw4QTXpm5bflzIubMWU130_provenance.
- NP1126503.RALsmwngbc0fyEwu9DAtxaOzlwVw4QTXpm5bflzIubMWU130_assertion wasDerivedFrom befree-2016 NP1126503.RALsmwngbc0fyEwu9DAtxaOzlwVw4QTXpm5bflzIubMWU130_provenance.
- NP1126503.RALsmwngbc0fyEwu9DAtxaOzlwVw4QTXpm5bflzIubMWU130_assertion SIO_000772 24210073 NP1126503.RALsmwngbc0fyEwu9DAtxaOzlwVw4QTXpm5bflzIubMWU130_provenance.
- NP1126503.RALsmwngbc0fyEwu9DAtxaOzlwVw4QTXpm5bflzIubMWU130_assertion evidence source_evidence_literature NP1126503.RALsmwngbc0fyEwu9DAtxaOzlwVw4QTXpm5bflzIubMWU130_provenance.
- NP1126503.RALsmwngbc0fyEwu9DAtxaOzlwVw4QTXpm5bflzIubMWU130_assertion description "[The effectiveness of the pro-drug FTY720 (known as fingolimod), approved for the treatment of multiple sclerosis, has become the gold standard for S1P-centric drugs, and will be used to illustrate the therapeutic value of modulating SphK1 and S1P receptor functions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1126503.RALsmwngbc0fyEwu9DAtxaOzlwVw4QTXpm5bflzIubMWU130_provenance.